Selling And Administration Expenses Cambio Fecha
Amgen USD 1.76B 424M 2023-12
Arrowhead Research USD 26.19M 595K 2023-12
AstraZeneca USD 3.91B 194M 2023-09
BioMarin Pharmaceutical USD 275.02M 51.1M 2023-12
Bristol-Myers Squibb USD 2.06B 126M 2023-12
Celldex Therapeutics USD 8.83M 611K 2023-12
Daiichi Sankyo JPY 141.03B 4.45B 2023-09
Eli Lilly USD 1.92B 120.7M 2023-12
Halozyme Therapeutics USD 37.61M 2.34M 2023-12
Heron Therapeutics USD 24.6M 11.84M 2023-09
Intrexon USD 9.2M 120K 2023-09
Ionis Pharmaceuticals USD 71.01M 1.06M 2023-12
Ligand Pharmaceuticals USD 15.99M 1.34M 2023-12
Neurocrine Biosciences USD 204.2M 17.6M 2023-09
Pfizer USD 4.47B 1.27B 2023-12
Regeneron Pharmaceuticals USD 737.7M 97.2M 2023-12
Rigel Pharmaceuticals USD 24.86M 1.45M 2023-09
Ultragenyx Pharmaceutical USD 76.83M 1.92M 2023-12
Veracyte USD 49.06M 9.55M 2023-12



Rigel Pharmaceuticals Gastos De Venta Y Administración - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2024.